Literature DB >> 1419471

Therapeutic use of atrial natriuretic factor.

J M Connell1, A G Jardine, D B Northridge.   

Abstract

Mesh：

Substances：

Year:  1992        PMID： 1419471      PMCID： PMC1381525          DOI： 10.1111/j.1365-2125.1992.tb04117.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  33 in total

1.  Antihypertensive activity of sinorphan.

Authors:  P Lefrançois; G Clerc; J Duchier; C Lim; J M Lecomte; C Gros; J C Schwartz
Journal:  Lancet       Date:  1990-08-04       Impact factor: 79.321

Review 2.  Role of endopeptidase-24.11 in the inactivation of atrial natriuretic peptide.

Authors:  A J Kenny; S L Stephenson
Journal:  FEBS Lett       Date:  1988-05-09       Impact factor: 4.124

3.  Clearance function of type C receptors of atrial natriuretic factor in rats.

Authors:  F A Almeida; M Suzuki; R M Scarborough; J A Lewicki; T Maack
Journal:  Am J Physiol       Date:  1989-02

4.  Atrial natriuretic factor-potentiating and antihypertensive activity of SCH 34826. An orally active neutral metalloendopeptidase inhibitor.

Authors:  E J Sybertz; P J Chiu; S Vemulapalli; R Watkins; M F Haslanger
Journal:  Hypertension       Date:  1990-02       Impact factor: 10.190

5.  Enkephalinase inhibition increases plasma atrial natriuretic peptide levels, glomerular filtration rate, and urinary sodium excretion in rats with reduced renal mass.

Authors:  H M Lafferty; M Gunning; P Silva; M B Zimmerman; B M Brenner; S Anderson
Journal:  Circ Res       Date:  1989-09       Impact factor: 17.367

6.  Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure.

Authors:  P G Cavero; K B Margulies; J Winaver; A A Seymour; N G Delaney; J C Burnett
Journal:  Circulation       Date:  1990-07       Impact factor: 29.690

7.  The atriopeptidase inhibitor UK 69,578 increases atrial natriuretic factor and causes a natriuresis in normal humans.

Authors:  A G Jardine; J M Connell; D Northridge; S G Dilly; N J Cussans; G Davidson; J Doyle; B L Leckie; A F Lever
Journal:  Am J Hypertens       Date:  1990-09       Impact factor: 2.689

8.  Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension.

Authors:  J E O'Connell; A G Jardine; G Davidson; J M Connell
Journal:  J Hypertens       Date:  1992-03       Impact factor: 4.844

Review 9.  Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones.

Authors:  E G Erdös; R A Skidgel
Journal:  FASEB J       Date:  1989-02       Impact factor: 5.191

10.  Low-dose infusion of atrial natriuretic factor in mild essential hypertension.

Authors:  G Tonolo; A M Richards; P Manunta; C Troffa; A Pazzola; P Madeddu; A Towrie; R Fraser; N Glorioso
Journal:  Circulation       Date:  1989-10       Impact factor: 29.690
View more
  1 in total

Review 1.  The role of the renin-angiotensin and natriuretic peptide systems in the pulmonary vasculature.

Authors:  R I Cargill; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.